NLRP3 and cystic fibrosis: Airway epithelial cells and monocytes bearing different CF-associated mutations displayed increased NLRP3-dependent IL-1β/IL-18 secretion, an effect reversed by either NLRP3 inflammasome pathway inhibitors or small-molecule inhibitors of ENaC [47].